Total Payments
$9,588
2023 Payments
$18.13
Companies
7
Transactions
32
Payment Breakdown by Category
Research$8,321 (86.8%)
Food & Beverage$637.25 (6.6%)
Travel$628.89 (6.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,321 | 17 | 86.8% |
| Food and Beverage | $637.25 | 10 | 6.6% |
| Travel and Lodging | $628.89 | 5 | 6.6% |
Payments by Type
Research
$8,321
17 transactions
General
$1,266
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $5,130 | 1 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $3,130 | 15 | $0 (2018) |
| Ironwood Pharmaceuticals, Inc | $594.20 | 3 | $0 (2018) |
| Ferring International Pharmascience Center US | $439.06 | 10 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $214.75 | 1 | $0 (2019) |
| CIPLA USA INC. | $61.44 | 1 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.13 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $18.13 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($18.13) |
| 2021 | $5,130 | 1 | Eli Lilly and Company ($5,130) |
| 2019 | $653.81 | 11 | Ferring International Pharmascience Center US ($439.06) |
| 2018 | $1,943 | 12 | Regeneron Pharmaceuticals, Inc. ($1,287) |
| 2017 | $1,843 | 7 | Regeneron Pharmaceuticals, Inc. ($1,843) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/22/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Gastroenterology | ||||||
| 07/12/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,130.00 | Research |
| Study: A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $60.73 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $50.56 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Travel and Lodging | In-kind items and services | $46.37 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: UROLOGY | ||||||
| 01/25/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $8.03 | General |
| Category: UROLOGY | ||||||
| 01/24/2019 | Ferring Pharmaceuticals Inc. | NOCDURNA (Drug) | Travel and Lodging | In-kind items and services | $214.75 | General |
| Category: UROLOGY | ||||||
| 01/24/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $103.84 | General |
| Category: UROLOGY | ||||||
| 01/24/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Travel and Lodging | In-kind items and services | $92.44 | General |
| Category: UROLOGY | ||||||
| 01/24/2019 | Ferring International Pharmascience Center US | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: UROLOGY | ||||||
| 07/22/2018 | CIPLA USA INC. | — | — | Cash or cash equivalent | $61.44 | Research |
| Study: A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MCG INHALATION POWDER (CIPLA LTD., INDIA) WITH ADVAIR DISKUS 100/50 MCG (GLAXOSMITHKLINE, USA) IN ASTHMA PATIENTS. | ||||||
| 07/20/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $113.53 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Food and Beverage | In-kind items and services | $318.87 | General |
| Category: Gastroenterology | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Travel and Lodging | In-kind items and services | $143.62 | General |
| Category: Gastroenterology | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Travel and Lodging | In-kind items and services | $131.71 | General |
| Category: Gastroenterology | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $190.45 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $84.99 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $50.04 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $38.38 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $20.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 04/27/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $20.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
| 03/23/2018 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $769.50 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $5,130 | 1 |
| A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Regeneron Pharmaceuticals, Inc. | $1,843 | 7 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | Regeneron Pharmaceuticals, Inc. | $1,287 | 8 |
| A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MCG INHALATION POWDER (CIPLA LTD., INDIA) WITH ADVAIR DISKUS 100/50 MCG (GLAXOSMITHKLINE, USA) IN ASTHMA PATIENTS. | CIPLA USA INC. | $61.44 | 1 |
About Dr. Thomas Jarrett, M.D
Dr. Thomas Jarrett, M.D is a Internal Medicine healthcare provider based in High Point, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932217239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Jarrett, M.D has received a total of $9,588 in payments from pharmaceutical and medical device companies, with $18.13 received in 2023. These payments were reported across 32 transactions from 7 companies. The most common payment nature is "" ($8,321).
Ad
Practice Information
- Specialty Internal Medicine
- Location High Point, NC
- Active Since 08/27/2006
- Last Updated 07/26/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1932217239
Products in Payments
- NOCDURNA (Drug) $653.81
- LINZESS (Drug) $594.20
- XIFAXAN (Drug) $18.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in High Point
Imran Haque, M.d, M.D
Internal Medicine — Payments: $18,695
Internal Medicine $18,695
Dr. Jeffrey Yourshaw, M.d, M.D
Internal Medicine — Payments: $12,650
Internal Medicine $12,650
Dr. Oscar Florendo, M.d, M.D
Internal Medicine — Payments: $11,971
Internal Medicine $11,971
Kurt Daniel, D.o, D.O
Internal Medicine — Payments: $7,198
Internal Medicine $7,198
Dr. William Smith, M.d, M.D
Internal Medicine — Payments: $6,941
Internal Medicine $6,941
Dr. Fernando Sanchez-Brugal, Md, MD
Internal Medicine — Payments: $6,214
Internal Medicine $6,214